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Abstract  
Background: The negative trials of vitamin C in Charcot-Marie-Tooth disease (CMT) type 1A 
have highlighted the lack of sensitive outcome measures. Neurofilaments are abundant 
neuronal cytoskeletal proteins and their concentration in blood is likely to reflect axonal 
breakdown. We therefore examined plasma neurofilament heavy chain (NfH) concentration 
as a potential biomarker in CMT. 
Methods: Blood samples were collected from healthy controls and patients with CMT over a 
2-year period. Disease severity was measured using the CMT Examination Score. An in-
house ELISA was used to measure plasma NfH levels. 
Results: There was no significant difference in plasma NfH concentrations between CMT 
patients and controls (P=0.449). There was also no significant difference in plasma NfH 
levels in the CMT group over 1 year (mean difference = -0.02, Standard error of the mean = 
4.44, P=0.98).  
Conclusions: Plasma NfH levels are not altered in patients with CMT and are not a suitable 
biomarker of disease activity. 
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Introduction 
Charcot-Marie-Tooth disease (CMT) is the commonest genetic neuromuscular disease; it has 
a population prevalence of 1 in 2500 (1).  Although no pharmacological treatments exist, 
there have been several successful pre-clinical trials in mouse models of the disease (2–5). 
Vitamin C was shown to be effective in a mouse model of CMT1A (6), but this effect was not 
borne out in several double-blind randomized placebo-controlled trials (7–10).  These trials, 
however, have highlighted the insensitivity of current outcome measures to detect changes 
in disease progression over a 2-year period and the need for a sensitive biomarker. 
To date, plasma neurofilament heavy chain (NfH) levels have been shown to be raised in 
several central nervous system diseases including amyotrophic lateral sclerosis (ALS) and 
optic neuritis (11–15). Neurofilaments are the most abundant neuronal cytoskeletal protein 
in peripheral nerves, and their concentration in blood likely reflects axonal breakdown and 
provides a biomarker of peripheral nerve disease (16).  In further support of this hypothesis 
has been the demonstration of raised plasma NfH levels in a mouse model of lower motor 
neuron degeneration and in patients with diabetic polyneuropathy (17,18). 
The aims of this study were to determine whether plasma NfH levels are elevated in 
patients with CMT. If they are raised, we questioned whether they correlate with disease 
severity and whether they change over a 12-month follow up period.  
Materials and methods 
This study was approved by The National Hospital for Neurology and Neurosurgery Research 
Ethics Committee/ Central London REC 3 09/H0716/61.  
Blood samples were collected prospectively, with informed consent, from CMT patients 
attending the inherited neuropathy clinic at the NHNN.  CMT1A is the commonest type of 
CMT and the only type of CMT in which clinical trials have taken place. Although it is 
classified as a demyelinating neuropathy, CMT1A patients were included in this study, as 
their clinical deficit is known to be due to axonal damage. Only patients with a genetically 
confirmed diagnosis of CMT were included, and patients with other neurological diseases 
were excluded.  The disease severity, as measured by the Charcot-Marie-Tooth Examination 
Score (CMTES, second version), was recorded at the same time as plasma was collected (19). 
The CMTES is a validated outcome measure for assessing the severity of CMT. It is a 
composite score that includes the patient’s symptoms and examination findings.  
 Blood samples were obtained from healthy relatives of patients attending the inherited 
neuropathy clinic and staff at the UCL Institute of Neurology.  Healthy subjects were 
excluded if they had co-existent neurological disease as determined by a symptom- and past 
medical history-based questionnaire.  Plasma from healthy controls was also acquired with 
informed consent from the relatives of patients with ALS recruited as part of a separate 
study [East London and the City Research Ethics Committee 1 (09/H0703/27)]. 
A modified in-house sandwich ELISA was used to measure plasma hyper-phosphorylated 
NfH levels in the plasma (SMI-34R, Covance, USA)(20).  
All statistical analysis was performed using SPSS version 14.00. Plasma NfH levels were 
compared using a Mann-Whitney U test, and correlation of plasma NfH and disease severity 
and age were assessed using Pearson correlation coefficients. 
Results 
A similar number of patients with CMT (n=90) and healthy controls (n=79) were included in 
this study. Controls were significantly older than the CMT cohort (P=0.039, t-test) although 
the mean difference was only 5 years. There was also a significant difference in the ratio of 
men to women in the 2 groups [46:44 (CMT), 56:23 (Controls), 𝜒2=6.876 P= 0.009], with 
significantly more women in the controls. Nevertheless, there were no gender differences in 
plasma NfH levels within the CMT (unpaired t-test, P=0.3) and control groups (P=0.9). The 
percentage of patients with demyelinating forms of CMT (71%) was higher than for axonal 
forms (29%).  
There was no difference in the primary outcome measure of plasma NfH concentration 
between patients with CMT (27.4 ng/ml) and controls (21.5 ng/ml) (P=0.449, Mann Whitney 
U test) and no significant difference in plasma NfH levels between patients with axonal (27.8 
ng/ml) and demyelinating (27.3 ng/ml) forms of CMT (P=0.833) (see Figure 1). 
There was a small but significant difference in the mean age of CMT patients (44) and 
controls (48.9) (P= 0.02, t-test), although there was no significant correlation between 
plasma NfH levels and age in the controls (Pearson correlation coefficient = -0.039, 
P=0.730).  
To determine whether the lack of a difference in plasma NfH levels in CMT is due to the 
inclusion of patients with a lower CMTES score (<10), and hence lower levels of axonal 
degeneration, NfH levels were correlated against the CMTES score.  Unexpectedly, there 
was a trend toward a reduction in NfH levels with increasing disease severity as defined by 
the CMTES (Pearson Rank -0.173, P=0.104) (Figure 1).  
There was no significant difference in plasma NfH levels in the CMT group over 1 year (mean 
difference = -0.02, SEM=4.44, paired t-test, P=0.98).  This is despite a mean increase in the 
CMTES of 1 point for all forms of CMT (SEM=0.41, P=0.01).  
Discussion 
A cross-sectional comparison of plasma NfH levels revealed no difference between CMT 
patients and controls.  There are several reasons why this may be the case.  First, CMT is a 
slowly progressive disease in comparison to more rapidly progressive neurodegenerative 
disorders in which plasma and serum NfH levels were elevated (15).  Second, the timing of 
clinical progression due to axonal degeneration and timing of sampling is critical, and this 
cohort might, while being systematic, not have covered random but clinically relevant 
events. The third possibility is that chronic release of NfH into the peripheral circulation 
induces an immune response that leads to the production of anti-NfH antibodies and a 
consequent reduction in detectable plasma NfH levels. This phenomenon has been 
observed in other neurological conditions, including primary and secondary progressive MS, 
in which higher antibody levels against neurofilament light chain (NfL) and NfH have 
recently been described (21,22). It is also worth noting that the mean age of subjects was 44 
years. It is possible that plasma NfH levels may be elevated in pediatric patients with CMT in 
whom the volume of distribution is smaller and in whom antibodies against NfH and NfL (if 
present) may not yet have been produced. 
Much of the work examining NfL and NfH has focused on levels in both plasma and CSF 
(23,24). It is possible that NfH levels are elevated in the CSF of patients with CMT but are 
degraded rapidly in the plasma. Against this hypothesis is the fact that CMT is a length-
dependent, dying-back neuropathy in which neurodegeneration occurs in the distal limbs.  
The degree of neurodegeneration at the level of the intradural nerve root is therefore likely 
to be low.  
In order for plasma NfH to be a biomarker of axonal degeneration in CMT there should be a 
significant difference between patients with CMT and controls, and the levels should 
correlate with disease severity. Unfortunately, plasma NfH is not higher in CMT patients 
than controls, and there is a decrease in plasma NfH with increasing disease severity. Plasma 
NfH levels are therefore not suitable as a biomarker of CMT disease severity or as a 
potential biomarker for natural history studies or clinical trials.  
Abbreviations: 
CMT = Charcot-Marie-Tooth disease 
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NfH = Neurofilament heavy chain 
CMTES = Charcot-Marie-Tooth examination score 
CMTNS = Charcot-Marie-Tooth neuropathy score 
ALS = Amyotrophic Lateral Sclerosis 
SEM = Standard error of the mean 
ELISA = Enzyme Linked Immuno- absorbant Assay 
NHNN = National Hospital for Neurology and Neurosurgery 
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 Figure 1. Plasma neurofilament heavy chain levels in patients with CMT versus controls. (A) 
the genetic breakdown of all CMT patients included in the study. (B) plasma NFH levels 
(black dots) of all CMT patients and controls. The horizontal dotted line shows mean plasma 
NfH levels of CMT patients (27.4 ng/ml) versus controls (21.5 ng/ml)(p=0.449). (C) plasma 
NfH levels plotted against disease severity as determined by the CMTES. Unexpectedly, 
there was a trend toward a reduction in NfH levels with increasing disease severity (Pearson 
Rank -0.173, P=0.104). (D) mean difference in plasma NfH levels over 1 year in 19 CMT 
patients and 10 controls. There was no significant difference in plasma NfH levels in CMT 
patients (mean difference = -0.02, P=0.98) or controls (mean difference=-7, P=0.37) over 1 
year. 
 
  
 
